FORTplus study: 2 x 2 Gy ISRT with obinutuzumab vs. 12 x 2 Gy ISRT with rituximab, a randomized, controlled, multicenter phase III study by the GLA (GLA 2022-05)-MedSci.cn

FORTplus study: 2 x 2 Gy ISRT with obinutuzumab vs. 12 x 2 Gy ISRT with rituximab, a randomized, controlled, multicenter phase III study by the GLA (GLA 2022-05)

König, L; Kieser, M; Dreyling, M; Scholz, C; Herfarth, K

STRAHLENTHERAPIE UND ONKOLOGIE, 2023; 199 (): S108

科室
- - 订阅+
  - 更多科室
工具
服务